Nigel Farage discusses concerns about COVID boosters
We use your sign-up to provide content in ways you’ve consented to and to improve our understanding of you. This may include adverts from us and 3rd parties based on our understanding. You can unsubscribe at any time. More info
Countries across the world have scaled up their booster vaccination campaigns in response to the Omicron variant. A strong body of evidence illustrates the effectiveness of the third dose against the variant, which has been shown to escape the immunity afforded by two shots. Naturally, rolling out a vaccination programme on this scale has meant a small number of people have experienced side effects.
The Australian Government’s Therapeutic Goods Administration (TGA) has been monitoring the side effects of the booster vaccine as it has made its way through the population.
The TGA closely monitors reports of suspected side effects (also known as adverse events) to the COVID-19 vaccines.
The safety body has concluded that “vaccination against COVID-19 is the most effective way to reduce deaths and severe illness from infection”.
Nonetheless, it has received approximately 600 reports of suspected adverse events identified as a third or booster dose.
The most common “adverse event” reported to the TGA following a booster dose is swollen lymph nodes (also called lymphadenopathy).
The side effect is characterised by swelling which may be noticed near the injection site, for example in an armpit, within a few days of vaccination.
“This is a normal and known side effect of vaccines and occurs when the immune system is stimulated,” notes the TGA.
According to the safety watchdog, swollen lymph nodes were observed in the clinical trials.
For Pfizer, this occurred “more frequently after a third or booster dose” (five percent of people) than after the first or second doses (less than one percent of people) in the clinical trials.
For Moderna), this occurred in up to 10 percent of people, reports the TGA.
According to the safety body, this side effect normally resolves without treatment after a week or so.
“People should seek medical attention if swelling persists for more than a few weeks to rule out other causes,” it advises.
Booster UK latest
The eligibility criteria for the booster vaccine has been extended to 16 and 17-year-olds from today, NHS England has said.
Invitations will initially be sent to the 40,000 adolescents who had a second vaccine dose at least three months ago.
Eventually more than 600,000 people aged 16 and 17 who have had two doses will be eligible for the booster.
More than seven in 10 people in this age group in England have had at least one dose – 889,700 in total.
Source: Read Full Article